5395232026-01-012026-03-315395232026-03-315395232025-03-315395232025-04-012026-03-315395232026-01-012026-03-31in-capmkt:OtherExpenses1Member5395232025-04-012026-03-31in-capmkt:OtherExpenses1Member5395232026-03-31OtherNoncurrentFinancialAssetsDomain15395232026-03-31OtherNoncurrentAssetsDomain15395232026-03-31OtherNoncurrentAssetsDomain25395232026-03-31OtherCurrentFinancialAssetsDomain15395232026-03-31OtherCurrentAssetsDomain15395232026-03-31OtherNoncurrentFinancialLiabilitiesDomain15395232026-03-31OtherNoncurrentFinancialLiabilitiesDomain25395232026-03-31OtherNoncurrentLiabilitiesDomain15395232026-03-31OtherCurrentFinancialLiabilitiesDomain15395232026-03-31OtherCurrentFinancialLiabilitiesDomain25395232026-03-31OtherCurrentLiabilitiesDomain15395232026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25395232025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25395232026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395232025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395232026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-282026-05-19INRMillionsQuarterlyFourth quarterSingle segmentThe Company is exclusively engaged in pharmaceutical business2026-05-2811:20:002026-05-2813:15:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31UnauditedConsolidated3603320000020007000003803390000089494000004977700000-14484000007121000000538800000105760000011259600000324557000005578200000-134970000042285000001216300000495400000171170000002516800000000-569000025111100001152700000366381000023646110001465000003497711000166100000239100000219.7719.770019.7719.77Notes to the Consolidated Financial results: <BR> <BR> 1.The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. <BR> <BR> 2.The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 27 May 2026 and subsequently approved by the Board of Directors at its meeting held on 28 May 2026. The auditors have issued an unmodified opinion on the financial results for the year ended 31 March 2026. <BR> <BR> The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. <BR> <BR> 3.Exceptional items includes: <BR> <BR> 1) During the quarter and year ended 31 March 2026 year, the Parent Company reviewed its investments in real estate; where recoverability is subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to Rs 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026. <BR> <BR> 2) During the year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Parent Company and its Indian subsidiaries assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. <BR> Based on this assessment, the Parent Company and its Indian subsidiaries have recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs 527.9 million in the quarter ended 31 December 2025 and an incremental impact of Rs 602.7 million in the quarter ended 31 March 2026 resulting in a total impact of Rs 1,130.6 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. The Parent Company and its Indian subsidiaries will continue to evaluate any further clarifications or implementation guidance issued in relation to the Labour Codes and account for the financial impact, if any, as appropriate. <BR> <BR> 3) The Group as part of its ongoing initiative of networking, strategy and optimisation of manufacturing facilities had identified divestment of its Indore facility and had impaired the same during financial year 2024. The said facility has been sold in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain (arising out of reversal of impairment loss) amounting to Rs142.9 million had been classified and disclosed as an exceptional item in the results for the year ended 31 March 2026. <BR> <BR> 4.Pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Parent Company and one of its Indian subsidiary; have decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax has been recognised at the substantially enacted rate as at 31 March 2026. <BR> <BR> 5.The Board of Directors at its meeting held on 28 May 2026 have declared a final dividend of Rs 10 (Rupees Ten only) per equity share (face value of Rs 2 each) in addition to the interim dividend Rs 43 (Rupees Forty Three only) per equity share (face value of Rs 2 each) declared on 13 February 2026. The final dividend is subject to approval at the ensuing annual general meeting of the Company. <BR> <BR> 6.The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.2025-04-012026-03-31AuditedConsolidated14712270000058335000001529562000003565390000016945000000-167120000028371100000160780000038206000003777180000012249900000030457200000-1748300000287089000006196600000-10190000005177600000023531300000000-1969000023511610000183790000025349510000230180110004936000002484181100050770000023910000020192.51192.5100192.51192.51Other Expenses11259600000Other Expenses377718000002694970000013791000000523640000065242000001438800000001131500000000121574000002347240000018193500000343040000086624500000333322000007373100000297911000002479100000148499000006630000025225200000797847000008988300000122105200000208729700000239100000137961900000138201000000528830000014348930000049245000000007844800000127693000004312100000151200000180800000174134000001131050000019714000002047040000022441800000821110000041963400000319170000020065000006654000004782700000065240400000208729700000Other Financial assets12157400000Current tax assets (net)799600000Other non-current assets2630800000Other financial assets25225200000Other current assets8988300000Other non-current financial liabilities4077000000Lease Liabilities3767800000Other non-current liabilities180800000Other current financial liabilities7742300000Lease liabilities468800000Other current liabilities31917000001607800000-2473100000-32887000000-87540000000001214200000000382060000001271300000000-160300000039164000004870000010910000000-14540000000-278760000025921300000-80000000629020000001963030000000000000130310000061726000000000000000059431300000745110000000000800000327630000000-16672100000000000003140100000654000000410400000613700000012348000000262100000-5034000000-2075800000-144600000-2220400000-1200900000-3421300000In respect of continuing operations:354600000In respect of discontinued operations:0354600000In respect of continuing operations:120900000In respect of discontinued operations:012090000011840000038100000Items that will be reclassified to profit or loss916500000916500000Items that will be reclassified to profit or loss175510000017551000000011527000001837900000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31